Verified July 2026 · Cited to primary sources
PT-141: Evidence Grade A — FDA-approved / proven in humans.
The honest verdict
PT-141 (bremelanotide) is an FDA-approved drug — Vyleesi (2019) — for HSDD in premenopausal women, so its evidence is Grade A. The honest caveats: the benefit on desire is modest, and the other uses it's sold for (men, nasal sprays) are off-label and unproven. Access it via a licensed provider, not gray-market vials.
PT-141 at a glance
- Class
- Synthetic melanocortin receptor agonist (bremelanotide)
- Mechanism
- Activates central melanocortin receptors (chiefly MC4R) in the brain to increase sexual desire and arousal — a centrally-acting libido peptide, not a vascular drug like the PDE5 inhibitors.
- Also known as
- Bremelanotide, Vyleesi, PT141
- Research applications
- Hypoactive sexual desire disorder (HSDD) in premenopausal women — its FDA-approved indication
- Libido/erectile support in men (off-label, gray-market; not an approved use)
- Forms
- subcutaneous injection, intranasal spray (compounded, off-label)
- Legal status
- FDA-approved
- WADA (anti-doping)
- Not prohibited
- Evidence grade
- Grade AFDA-approved / proven in humans
How we grade evidence
Every grade is assigned by a fixed A–F rubric — human-trial strength, not hype or affiliate status. Last verified July 6, 2026.
What is PT-141?
One of only two FDA-approved peptides in this space — proven to raise sexual desire in premenopausal women, but the benefit is modest and the off-label hype outruns it.
Activates central melanocortin receptors (chiefly MC4R) in the brain to increase sexual desire and arousal — a centrally-acting libido peptide, not a vascular drug like the PDE5 inhibitors.
How strong is the evidence for PT-141?
Grade A: FDA-approved (Vyleesi, 2019) on two pivotal Phase 3 RCTs (rule 1 fired — FDA-approved for ≥1 indication). Note the honest caveat: the trials met their endpoints but the real-world effect on desire was modest, and approval is only for premenopausal-women HSDD, not the other uses it is sold for off-label.
Primary sources (2)
Is PT-141 legal? (Status July 2026)
Prescription via a licensed provider.
What does PT-141 cost — and how do you access it legally?
Typical cost
Branded Vyleesi commonly ~$900 for four auto-injectors (retail)
Branded Vyleesi retail runs roughly $900 for a four-dose pack (verify current list price with a licensed provider). Compounded PT-141 is sold cheaper but is off-label and unverified; we don't quote or link gray-market sources.
How to access it legally
PT-141is FDA-approved, so the legal route is a prescription from a licensed provider — not a research vial. We don't currently have a vetted partner to link for it, so there's no button here; ask a licensed clinician about the branded product. We never point you to gray-market or compounded off-label sources.
Is PT-141safe? Side effects & risks
Well-characterized in trials. Common: nausea (the most frequent side effect), flushing, and headache. Can cause transient increases in blood pressure and decreases in heart rate — caution in uncontrolled hypertension or cardiovascular disease. Focal hyperpigmentation with repeated dosing. Off-label gray-market use (e.g. in men, or via compounded nasal sprays) falls outside the approved, studied population.
Medical disclaimer: This page is independent editorial information, not medical advice, and Best Peptide For That is not a medical provider. We do not provide dosing. Talk to a licensed clinician before starting, stopping, or changing any peptide or medication. Full medical disclaimer.
FAQ
PT-141 FAQ
Is PT-141 FDA approved?
Yes, as Vyleesi (bremelanotide), FDA-approved in June 2019 to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. That is its only approved use — the off-label uses it's marketed for, including in men, are not FDA-approved.
Does PT-141 actually work for libido?
In its two Phase 3 trials it significantly improved sexual desire versus placebo in premenopausal women with HSDD (Grade A evidence), but the real-world effect was modest. There is no comparable approval-grade trial evidence for the men's-libido use it's often sold for.
What are the side effects of PT-141?
The most common is nausea, along with flushing and headache. It can transiently raise blood pressure and lower heart rate, so it's cautioned in uncontrolled hypertension or heart disease, and repeated use can cause focal skin darkening.
Keep reading
Tesamorelin
One of only two FDA-approved peptides in this space — proven to cut visceral fat, but approved for a narrow HIV indication.
Grade BSermorelin
The "gentler," formerly-FDA-approved GH-axis peptide — the best-evidenced option you can still legally get through a compounding pharmacy.
Grade BRetatrutide
The next-generation weight-loss peptide with the strongest efficacy signal — but it is investigational and not yet available by any legal route.
The monthly peptide evidence brief.
What the research and the FDA actually say — one short email a month. Unsubscribe anytime.
No spam. We never sell your email. Editorial policy.